Department of Dermatology, Center for Cutaneous Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
Department of Dermatology, Center for Cutaneous Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
Hematol Oncol Clin North Am. 2019 Aug;33(4):669-686. doi: 10.1016/j.hoc.2019.04.004. Epub 2019 May 23.
Non-Hodgkin's lymphoma (NHL) encompasses a diverse collection of systemic and primary cutaneous lymphomas. Cutaneous T-cell lymphomas (CTCLs) represent about 13% of all NHLs, which are further subdivided into a heterogeneous group with vastly different presentations and histologic features. Diagnosis requires integration of clinical, pathologic, and molecular features. Among CTCLs, mycosis fungoides and Sézary syndrome are the most prevalent. Treatment is aimed at limiting morbidity and halting disease progression. Hematopoietic stem cell transplantation is the only therapy with curative intent.
非霍奇金淋巴瘤(NHL)包括一系列不同的系统性和原发性皮肤淋巴瘤。皮肤 T 细胞淋巴瘤(CTCL)占所有 NHL 的约 13%,进一步细分为一组具有非常不同表现和组织学特征的异质性群体。诊断需要整合临床、病理和分子特征。在 CTCL 中,蕈样真菌病和 Sezary 综合征最为常见。治疗旨在限制发病率并阻止疾病进展。造血干细胞移植是唯一具有治愈意图的治疗方法。